Atlas Trials

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Clinical trial NCT05720026 · UNKNOWN

Trial details

NCT number
NCT05720026
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2023-01-09
Primary completion
2025-08-29
Enrollment
560

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.